AI Article Synopsis
- Treatment for metastatic melanoma is complicated by drug resistance, often needing radiotherapy, which still results in frequent relapses.
- Preclinical models and patient data indicate that treating with BRAF inhibitors before radiotherapy leads to more rapid tumor relapse compared to the reverse order.
- JARID1B/KDM5B is identified as a marker for resistance, promoting cell survival and affecting treatment outcomes based on the order of therapies.
Article Abstract
Introduction: Treatment of patients with metastatic melanoma is hampered by drug-resistance and often requires combination with radiotherapy as last-resort option. However, also after radiotherapy, clinical relapses are common.
Methods & Results: Our preclinical models indicated a higher rate of tumour relapse when melanoma cells were first treated with BRAF inhibition (BRAFi) followed by radiotherapy as compared to the reverse sequence. Accordingly, retrospective follow-up data from 65 stage-IV melanoma patients with irradiated melanoma brain metastases confirmed a shortened duration of local response of mitogen-activated protein kinase (MAPK)-inhibitor-pretreated compared with MAPK-inhibitor-naïve intracranial metastases. On the molecular level, we identified JARID1B/KDM5B as a cellular marker for cross-resistance between BRAFi and radiotherapy. JARID1B cells appeared more frequently under upfront BRAFi as compared with upfront radiation. JARID1B favours cell survival by transcriptional regulation of genes controlling cell cycle, DNA repair and cell death.
Conclusion: The level of cross-resistance between combined MAPK inhibition and radiotherapy is dependent on the treatment sequence. JARID1B may represent a novel therapy-overarching resistance marker.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejca.2018.12.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance.
Virus Evol
November 2024
Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Herestraat 49 box 1043, Leuven 3000, Belgium.
The widespread use of antivirals in immunocompromised individuals has led to frequent occurrences of drug-resistant herpes simplex virus 1 (HSV-1) infections. Current antivirals target the viral DNA polymerase (DP), resulting in cross-resistance patterns that emphasize the need for novel treatment strategies. In this study, we assessed whether combining antivirals with different targets affects drug resistance emergence by passaging wild-type HSV-1 under increasing concentrations of acyclovir (ACV), foscarnet (phosphonoformic acid, PFA), or the helicase-primase inhibitor pritelivir (PTV), individually or in combination (ACV + PTV or PFA + PTV).
View Article and Find Full Text PDFpotentiation of tetracyclines in by RW01, a new cyclic peptide.
Antimicrob Agents Chemother
December 2024
Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
The pipeline for new drugs against multidrug-resistant remains limited, highlighting the urgent need for innovative treatments. New strategies, such as membrane-targeting molecules acting as adjuvants, aim to enhance antibiotic effectiveness and combat resistance. RW01, a cyclic peptide with low antimicrobial activity, was selected as an adjuvant to enhance drug efficacy through membrane permeabilization.
View Article and Find Full Text PDFUnderstanding Bacterial Resistance to Heavy Metals and Nanoparticles: Mechanisms, Implications, and Challenges.
J Basic Microbiol
December 2024
Department of Infectious Diseases and Microbial Genomics, NITTE (Deemed to be University), NITTE University Centre for Science Education and Research, Paneer Campus, Deralakatte, Mangaluru, India.
Antimicrobial resistance is a global health problem as it contributes to high mortality rates in several infectious diseases. To address this issue, engineered nanoparticles/nano-formulations of antibiotics have emerged as a promising strategy. Nanoparticles are typically defined as materials with dimensions up to 100 nm and are made of different materials such as inorganic particles, lipids, polymers, etc.
View Article and Find Full Text PDFGenome-wide identification of bacterial genes contributing to nucleus-forming jumbo phage infection.
Nucleic Acids Res
December 2024
Department of Microbiology and Immunology, University of Otago, PO Box 56, Dunedin 9054, New Zealand.
The Chimalliviridae family of bacteriophages (phages) form a proteinaceous nucleus-like structure during infection of their bacterial hosts. This phage 'nucleus' compartmentalises phage DNA replication and transcription, and shields the phage genome from DNA-targeting defence systems such as CRISPR-Cas and restriction-modification. Their insensitivity to DNA-targeting defences makes nucleus-forming jumbo phages attractive for phage therapy.
View Article and Find Full Text PDFField-evolved resistance to neonicotinoids in the mosquito, Anopheles gambiae, is associated with mutations of nicotinic acetylcholine receptor subunits combined with cytochrome P450-mediated detoxification.
Pestic Biochem Physiol
December 2024
Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX, USA. Electronic address:
New insecticides prequalified for malaria control interventions include modulators of nicotinic acetylcholine receptors that act selectively on different subunits leading to variable sensitivity among arthropods. This study aimed to investigate the molecular mechanisms underlying contrasting susceptibility to neonicotinoids observed in wild populations of two mosquito sibling species. Bioassays and a synergist test with piperonyl butoxide revealed that the sister taxa, Anopheles gambiae and An.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!